The G 1 cyclins, cyclin D1 and E, are rate limiting for progression through G 1 phase of the cell cycle in breast epithelial cells and are oncogenic when expressed in the mammary epithelium of transgenic mice. These genes are frequently overexpressed in clinical breast cancer where overexpression appears to be associated with speci®c disease phenotypes, altered responsiveness to therapeutic intervention and patient survival. In order to investigate the functional correlates of cyclin D1 and cyclin E overexpression we employed a panel of normal, immortalized and neoplastic breast epithelial cell lines to examine the relationships between cyclin gene expression, cyclin-CDK complex formation and CDK activity. In agreement with earlier studies cyclin D1 and E expression varied over an approximately tenfold range among the 18 cell lines studied. There was no apparent relationship, however, between cyclin D1 expression and the in vitro activity of its major kinase partner, Cdk4, although MDA-MB-134 cells displayed the highest level of both cyclin D1 expression and Cdk4 activity. Similarly, there was no signi®cant relationship between cyclin E expression and cyclin E-Cdk2 activity. Fractionation of whole cell lysates by gel ®ltration chromatography revealed that *90% of the cyclin E protein was present in inactive complexes containing the CDK inhibitors p21 and p27. Much of the small fraction of active cyclin E protein was of very high apparent molecular mass, 4400 kDa, suggesting that formation of these complexes is a more important determinant of cyclin E-Cdk2 activity than cyclin E abundance. These data suggest that properties of cyclins D1 and E in addition to their ability to activate Cdk4 and Cdk2 may contribute to the eects of overexpression on the breast cancer phenotype.
Introduction
Many recent attempts to identify genetic alterations which may be important in the aetiology of breast cancer have focused on molecules that control cell cycle progression e.g. the cyclins, cyclin-dependent kinases (CDKs) and cyclin-dependent kinase inhibitors (CKIs) that regulate transition through the G 1 phase of the cell cycle (Hunter and Pines, 1994; Sherr, 1996) . The main G 1 phase cyclin-CDK complexes are the D-type cyclins (D1, D2 and D3) complexed with Cdk2, Cdk4 or Cdk6 and cyclin E-Cdk2 (Sherr and Roberts, 1995; Sherr, 1996) . These complexes phosphorylate speci®c substrates, of which the retinoblastoma gene product pRB has been the most extensively studied (Weinberg, 1995) . The periodic accumulation and destruction of the regulatory cyclin subunit is the ®rst level of control of cyclin-CDK complex formation and activation. In addition, the catalytic kinase subunit requires phosphorylation and dephosphorylation of key residues for complete activation (Morgan, 1995) . Finally, two families of low molecular weight CKIs have been described (Sherr and Roberts, 1995 ) speci®cally inhibit Cdk4 and Cdk6, competing with the D-type cyclins for binding to these CDKs (Sherr and Roberts, 1995) . The other family, including p21 (Waf1, Cip1, Sdi1) and p27 (Kip1) display broader speci®city, bind to both cyclin and CDK rather than the CDK only, and inhibit kinase activity depending on the stoichiometry of binding (Sherr and Roberts, 1995) . Recently, an additional role for the latter family of proteins as assembly factors has been identi®ed by the demonstration that p21 and p27 promote the association of Cdk4 with cyclin D1 and stabilize the complex .
The overexpression of both cyclin D1 and cyclin E has been documented in human breast cancer. Cyclin D1 overexpression is an early event in the evolution of breast malignancy (Alle et al., 1997) and occurs in 40 ± 50% of primary breast tumours (Buckley et al., 1993; Bartkova et al., 1994; Gillett et al., 1994) . Cyclin E is abnormally expressed in a signi®cant fraction of breast cancers and is a potential marker of poor prognosis in primary breast cancer (Keyomarsi and Pardee, 1993; Keyomarsi et al., 1994; Nielsen et al., 1996; Porter et al., 1997) . Overexpression in breast cancer is not, however, a feature of all G 1 cyclins, since cyclin D3 expression is similar in normal breast cells and breast cancer cells (Buckley et al., 1993; Bartkova et al., 1996) . CKIs are potential tumour suppressor genes and low levels of p27 have been related to poor prognosis in breast cancer (Catzavelos et al., 1997; Fredersdorf et al., 1997; Porter et al., 1997; Tan et al., 1997) .
Studies in transgenic mice have shown that overexpression of cyclin D1 or cyclin E in the mammary gland leads to hyperplasia and eventual mammary carcinoma (Wang et al., 1994; Bortner and Rosenberg, 1997) , demonstrating that these cyclins can be oncogenic for mammary epithelium. Acute induction of G 1 cyclins leads to an increase in the rate of G 1 transit (reviewed in Hunter and Pines, 1994; Sherr and Roberts, 1995; Sherr, 1996) . Most cells induced to overexpress cyclins D1 or E show an accumulation of active cyclin D1-Cdk4 and cyclin E-Cdk2 complexes and an increase in pRB phosphorylation (Ohtsubo and Roberts, 1993; Matsushime et al., 1994; Resnitzky et al., 1994; Resnitzky and Reed, 1995; Musgrove et al., 1996) . However, despite numerous observations of accelerated G 1 phase progression following cyclin overexpression, there are exceptions to this trend. For example, overexpression of cyclin D1 or cyclin E in certain mouse and human mammary epithelial cell lines inhibits cell cycle progression (Han et al., 1995 Sgambato et al., 1996 Sgambato et al., , 1997 . Thus the phenotypic eects of cyclin overexpression can be dependent on cell context, perhaps due to dierences in the expression levels of inhibitors or activators of cyclin-CDK complexes.
Support for this concept comes from data on clinical breast cancer where the phenotype of cyclin D1-overexpressing cancers does not ®t well with that expected from studies of ectopic overexpression of cyclin D1 in cultured cells. In primary breast cancers cyclin D1 is associated with estrogen receptor (ER) positivity, an indicator of good prognosis, and therefore is likely to be a marker for a more dierentiated, rather than a highly proliferative, more aggressive phenotype (Hui et al., 1996; Michalides et al., 1996) . Furthermore, in one study cyclin D1 protein overexpression correlated with improved overall survival (Gillett et al., 1996) and another showed a trend for improved breast cancerspeci®c survival (Nielsen et al., 1997) , although others failed to identify such a relationship (McIntosh et al., 1995; Michalides et al., 1996) . In contrast, high cyclin E expression occurs predominantly in ERnegative breast cancers (Nielsen et al., 1996 (Nielsen et al., , 1997 . Generally, high cyclin E and low cyclin D1 expression was found in cancers with high p16 levels and dysfunctional pRB, and patients with breast cancers of this phenotype tended to fare poorly over an observation period of 53 months, indicating that this molecular pro®le predicts for a more aggressive phenotype (Nielsen et al., 1997) . However, overexpression of cyclin E does not necessarily correlate with increased proliferation (Dutta et al., 1995) . In an attempt to identify the functional consequences of cyclin D1 and E overexpression in breast cancer we have used a panel of breast cancer cell lines as a model for the divergent phenotypes present in clinical breast cancer and examined the relationship between cyclin overexpression, cyclin-CDK complex formation, CDK activity and growth parameters. Surprisingly, cyclin overexpression was not necessarily associated with increased CDK activity.
Results

Cyclin, CDK and CKI inhibitor expression in 18 breast epithelial cell lines
Normal breast epithelial cell lines (184, HMEC 219.4), immortalized lines (184B5, 184A1, HBL-100) and a range of breast cancer cell lines of various phenotypes were initially characterized by determining the relative expression of the cyclins for which previous evidence of altered expression in breast cancer was strongest, i.e. cyclin D1 and cyclin E, and their major kinase partners, Cdk2, Cdk4 and Cdk6. The other CDKs to which these cyclins can bind i.e. Cdc2 and Cdk5, were also examined since these might, by competition with Cdk2, Cdk4 and Cdk6 for cyclin binding, aect the formation of active CDK complexes. Finally, p21 and p27 were examined because of their potential roles as assembly factors and in view of evidence for altered expression of p27 in breast cancer.
Cyclin D1 protein was markedly overexpressed in the MDA-MB-134 cell line, while two cell lines lacking functional pRB (HBL 100, BT 549) expressed little cyclin D1 protein (Figure 1 , Table 1 ). The MDA-MB-157 cell line was the only one examined that had exceptionally high levels of cyclin E mRNA and protein ( Figure 1 , Table 1 ). In contrast there was little dierence in the expression levels of Cdc2, Cdk2 and Cdk4 although a number of the breast cancer cell lines expressed higher levels than the normal cell strains (Figure 1 , Table 1 ). The putatively neuronspeci®c CDK, Cdk5, was detectable in the normal breast epithelial cell line 184 and the two immortalized derivatives of this cell line, 184B5 and 184A1 on blots exposed longer than that shown in Figure 1 . Cdk5 was relatively abundant in several of the breast cancer cell lines, namely MDA-MB-134, -157, -453 and -468, and detectable in the remainder ( Figure 1 , Table 1 ). The 184, 184B5 and 184A1 cell lines expressed readily detectable Cdk6 but it was only very faintly detected in the MCF-7, MDA-MB-134 and MDA-MB-361 cell line. Some of the CDK antibodies detected faint slower migrating bands indicating dierent phosphorylation states but smaller truncated forms of the CDKs were Cyclin D1   p27   p21   Cdk4  184  184B5  MDA-MB-134  MDA-MB-361  MDA-MB-330  MDA-MB-157  HBL-100  MDA-MB-231  MCF-7  MCF-7M  T-47D  BT-474  BT-549   184  184B5  MDA-MB-134  MDA-MB-330  MDA-MB-231  MDA-MB-157  MDA-MB-361  BT-549  BT-474  T-47D  MCF-7  MCF-7M  HBL-100 Cdk5 Cdk6
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Cdc2 Figure 1 Expression of cyclins, CDKs and CDK inhibitors in breast epithelial cell lines. Western blot analyses were performed on lysates from proliferating cells harvested at sub-con¯uence. Equal amounts of cleared cell lysate from each cell line were separated by SDS ± PAGE, transferred to nitrocellulose and blotted for the proteins indicated not detected in any of these cell lines. Thus, with the exception of Cdk6, all of the CDKs were moderately overexpressed in a number of the cancer cell lines when compared to the normal breast epithelial cell strains but large variations in their expression were not observed. The expression of the CKIs p27 and p21 showed greater variance than that of the CDKs. In 184 normal breast epithelial cells p21 protein was expressed at moderate levels but it was expressed at very low levels or undetectable in BT-474, BT-549, MDA-MB-157 and MDA-MB-231 cells (Figure 1 , Table 1 ). In contrast p27 was elevated in the cancer cell lines in comparison with 184 normal breast epithelial cells (Figure 1 , Table  1 ). The data in Figure 1 also suggested a tendency for cell lines displaying high cyclin D1 expression to also express high levels of p27 and p21. Further examination of this relationship demonstrated statistically signi®cant correlations between the expression of cyclin D1 and both p21 and p27 (P=0.010 and P=0.016, respectively). In marked contrast, there was no correlation between cyclin E expression and either p21 or p27 levels (P=0.445 and P=0.853, respectively).
Apparent lack of association between cyclin D1 expression and Cdk4 activity
The rise in p21 and p27 levels with increasing cyclin D1 expression suggested that cyclin D1-associated kinase activity might not increase with overexpression of cyclin D1 protein. Most of the cyclin D1-associated kinase activity in these breast cancer cell lines arises from cyclin D1-Cdk4 complexes since cyclin D1-Cdk6 complexes are not usually present and cyclin D1-Cdk2 complexes are inactive (Higashi et al., 1996) . Furthermore, although Cdk4 also forms complexes with cyclins D2 and D3, cyclin D2 is not usually expressed and cyclin D3 exhibits little change in expression levels across the range of breast cancer cell lines examined here (Buckley et al., 1993) . Therefore, Cdk4 activity was examined in cell lines selected to represent a range of cyclin D1 expression using an in vitro kinase assay with recombinant GST-pRB substrate (Figure 2a and b). These experiments indicated that in six of the seven cell lines Cdk4 activity was comparable with that in 184 normal breast epithelial cells, although the cyclin D1 levels varied by *2-fold. The exception was the MDA-MB-134 cell line, which exhibits *5-fold overexpression of cyclin D1 protein and had a 2.5-fold increase in Cdk4 activity. Unfortunately, there were no breast cancer cell lines available with between 2 ± 5-fold overexpression of cyclin D1, precluding determination of the relationship with Cdk4 activity over this range of cyclin D1 overexpression. Thus in the range of cell lines available there was very littlē uctuation in the level of Cdk4 activity compared to the much greater range of cyclin D1 protein expression and no strong relationship between Cdk4 activity and cyclin D1 expression was found ( Figure  2c ).
Lack of association between cyclin E expression and cyclin E-associated kinase activity
The relationship between cyclin E expression and cyclin E-associated kinase activity was next examined. Cyclin E immunocomplexes were used in in vitro kinase assays with histone H1 as substrate (Figure 3a and b) . There was a greater variation in cyclin E-associated kinase activity than for Cdk4 activity in the same cell lines. Notably, 184 normal breast epithelial cells had 2 ± 4-fold less cyclin Eassociated kinase activity than the six breast cancer cell lines, despite having comparable levels of cyclin E protein. Conversely, although the MDA-MB-157 cell line expressed *6-fold more cyclin E than the remaining cell lines, the cyclin E-associated kinase activity was no greater than that in MDA-MB-134 and MDA-MB-231 cells. Thus, there was no relationship between cyclin E protein expression and cyclin Eassociated kinase activity among the cell lines studied (Figure 3c ). Cyclin D1 and E expression levels are not correlated with rates of cell proliferation
Constitutive overexpression of G 1 phase cyclins might be expected to lead to an increased S phase fraction and decreased population doubling time. Thus, the relationship between these parameters and cyclin levels was examined for a panel of breast epithelial cell lines ( Table  2 ). The majority of cell lines had an S phase fraction of *30%, with neither MDA-MB-134 nor MDA-MB-157 displaying a signi®cant increase in %S phase despite marked overexpression of cyclin D1 and cyclin E, respectively. Similarly, there was no relationship between the overexpression of cyclin D1 or cyclin E and population doubling times, with the MDA-MB-157 and MDA-MB-134 cell lines displaying longer doubling times than the majority of the other breast cancer cell lines. Hence under optimal growth conditions there was no apparent growth advantage for the cell lines with high levels of G 1 cyclins. Similarly, there was no apparent relationship between increased CDK activity and increased %S phase or reduced doubling time among the cell lines studied (data not shown).
Composition of cyclin D1 complexes
To investigate possible reasons for the apparent lack of correlation between cyclin D1 protein expression and Cdk4 activity, the composition of cyclin D1-containing complexes was examined by immunoprecipitating cyclin D1 from cell lines chosen to represent a range of cyclin D1 protein expression levels, including two cell lines with SV40 large T antigen-bound pRB and mutant pRB that lack signi®cant cyclin D1 expression (HBL-100 and BT-549) as negative controls. The cell lines expressing the highest levels of cyclin D1 (e.g. MDA-MB-134, MCF-7) also displayed increased amounts of co-immunoprecipitating Cdk4, p27 and p21 ( Figure idea that the cyclin is the rate-limiting factor in the formation of cyclin D1-Cdk4 complexes. The amount of p21 and p27 bound to cyclin D1 was proportional to both the level of cyclin D1 (P=0.003 and 0.005, respectively) and the levels of each inhibitor expressed in the cell line (P=0.0001 and P=0.003, respectively). Since the expression levels of cyclin D1 and p21 or p27 are correlated (see above) the number of cyclin D1/p21 or cyclin D1/p27 complexes re¯ects the abundance of both components. There were, however, exceptions to these relationships. For example, in the MDA-MB-157 cell line there was little evidence for association of Cdk4, p21, or p27 with cyclin D1 (Figure 4a ) despite expression of these proteins at levels similar to those observed in other cell lines where complex formation was evident ( Figure 1 ). This was investigated further below (see Figure 8a ). In contrast, 184 normal breast epithelial cells had an abundance of p21 bound to cyclin D1. Cyclin D1-Cdk2 complexes were detected in nine of the 13 cell lines. Like the amount of Cdk4, the amount of Cdk2 bound to cyclin D1 correlated with the level of cyclin D1 protein in each cell line (P=0.012) ( Figure  4b) and not with the level of Cdk2 in the total cell
Figure 3 Cyclin E-associated kinase activity in a range of breast epithelial cell lines. Cyclin E immunocomplexes from seven exponentially growing breast epithelial cell lines were used in an in vitro kinase assay with histone H1 as substrate. (a) Representative autoradiogram of histone phosphorylation. Each sample is shown with its paired negative control, a duplicate lysate sample that was incubated with beads alone i.e. no anti-cyclin E antibody. (b) Graphical presentation of cyclin E-associated kinase activity in the range of cell lines examined. The bar histograms are the mean value and standard deviation of three independent experiments. (c) Relationship between the mean cyclin E-associated kinase activity in a cell line and the cyclin E level in the corresponding lysate even when both components were expressed at similar levels to those in the 184 cells (compare Figures 1 and  4) . Similarly cyclin D1-Cdk5 complexes were only detected in the cyclin D1 overexpressing cell line, MDA-MB-134 (not shown), although this CDK was expressed at similar levels in some of the other cell lines (e.g. MDA-MB-157).
There was a signi®cant correlation between the amount of p27 and Cdk4 present in cyclin D1 complexes (P=0.001) (Figure 4b) but not between the amount of p27 and Cdk2 binding to cyclin D1 (P=0.696). However, the amount of Cdk2 bound to cyclin D1 was related to the amount of p21 in cyclin D1 complexes (P=0.0001) such that those cell lines that did not form cyclin D1-Cdk2 complexes had relatively little p21 in the cyclin D1 complexes ( Figure  4b ). In contrast, there was no relationship between the level of p21 in cyclin D1 complexes and the amount of Cdk4 binding to cyclin D1 (P=0.116). These results imply that p21 and p27 preferentially bind to, or facilitate the binding of, cyclin D1-Cdk2 or cyclin D1-Cdk4 complexes, respectively. Overall these data suggest similar composition but altered abundance for cyclin D1-containing complexes across the range of cell lines examined.
Composition of cyclin E complexes
The composition of cyclin E complexes was also examined in an eort to understand the discordance between cyclin E expression and associated kinase activity. There was a strong correlation between the amount of cyclin E immunoprecipitated from each cell lysate and the level of Cdk2 bound (P=0.0002) ( Figure  5b) . Cyclin E-Cdc2 complexes were only detected in T-47D and MCF-7 cell lines (data not shown). No cyclin E-Cdk4 complexes were observed even in the MDA-MB-157 cell line displaying marked overexpression of cyclin E. There was no correlation between the amount of cyclin E and p21 in the immune complexes (P=0.276) but there was a relationship between cyclin E levels and the amount of cyclin E-associated p27 (P=0.0001) (Figure 5b ). In contrast with the lack of relationship between Cdk2 and p27 in cyclin D1 complexes, the amount of Cdk2 and p27 binding to cyclin E was correlated (P=0.0001). The 184 normal breast epithelial cell line was the exception to these patterns with a relative excess of p21 but very little p27 in the cyclin E immune complexes. These results suggest that the unexpectedly low level of cyclin Eassociated kinase activity in some of the cell lines with high cyclin E expression was not due to a lack of formation of cyclin E-Cdk2 complexes but rather may result from the presence of CKIs (particularly p27) in these complexes.
Gel ®ltration chromatography separates active and inactive cyclin E complexes
To determine what fraction of cyclins D1 and E resided in active complexes, cell lysates were fractionated by gel ®ltration chromatography. The cell lines selected included breast cancer cell lines that overexpress cyclin D1 (MDA-MB-134), or cyclin E (MDA-MB-157), cell lines with more moderate expression of both cyclins D1 and E (MCF-7 and T-47D) and a normal breast epithelial cell strain (184). Aliquots of fractions from a Superdex 200 column were used for Western blotting, cyclin E and cyclin D1 immunoprecipitation studies and kinase assays. While there were clear dierences in the elution patterns of the cyclins, CDKs and CKIs in these cell lines some features were relatively consistent and are illustrated on the data obtained using MCF-7 cell lysate ( Figure 6 ). Cyclin D1 and cyclin E were typically present as single broad peaks of *100 ± 250 kDa apparent molecular weight ( Figure 6 ). Similarly, p21 and p27 eluted as broad peaks of mobility similar to the cyclins ( Figure 6 ). In contrast, the majority of Cdk4 and Cdk2 eluted in fractions 11 ± 13, corresponding to their native molecular weight (*35 kDa) although signi®cant amounts coeluted with the cyclins and CKIs (Figure 6 ). Like the MCF-7 cell line, the T-47D and 184 cell lines had the majority of cyclin D1 protein eluting as one broad peak of *150 ± 200 kDa (Figure 7a ). In contrast, the cyclin D1 protein in MDA-MB-157 cells was predominantly in lower molecular weight fractions with the peak eluting at 50 ± 100 kDa (Figure 7a ). Cyclin D1 generated by in vitro translation in rabbit reticulocyte lysate also eluted at an apparent molecular weight of 50 ± 100 kDa, suggesting that the lower molecular weight cyclin D1 in the MDA-MB-157 cell line sample is likely to represent free (i.e. non-CDK bound) cyclin D1. This cell line overexpresses p16, which likely competed with cyclin D1 for Cdk4, thus preventing cyclin D1-Cdk4 complex formation (Musgrove et al., 1995; Gray-Bablin et al., 1996) . MDA-MB-134 cells displayed a very broad distribution of cyclin D1 protein across the fractions, including some of apparent molecular mass 4100 kDa indicating that some of the overexpressed protein is free in this cell line. Approximately 20% of the cyclin D1 protein in the MDA-MB-134 was also present at very high molecular weights, 4300 kDa. Similarly, in MDA-MB-134 cells Cdk4 protein had a broad distribution across the elution pro®le, although in most of the cell lines there was a peak of Cdk4 protein eluting at *150 ± 200 kDa, coeluting with cyclin D1. A small proportion of Cdk4 eluted at an apparent molecular mass of 40 ± 70 kDa (fractions 9 and 10), particularly in the MDA-MB-134 and MDA-MB-157 samples and may represent Cdk4 bound to small proteins such as the INK4 family of inhibitors. In all cell lines some free Cdk4 eluted at the native molecular weight (*35 kDa, fractions 11 ± 13).
For four of the ®ve cell lines examined, the majority of cyclin E protein eluted as a major peak of *200 kDa apparent molecular mass (fractions 4 ± 6) but cyclin E was also present at very high molecular weight (4400 kDa, fractions 1 and 2, Figure 7b) . Notably, the 184 cell line had relatively more cyclin E in these very high molecular weight fractions than the other cell lines (*20% of the total). In the T-47D cells the peak of cyclin E was much broader, extending from *300 ± 100 kDa (fractions 4 ± 8, Figure 7b) . A signi®cant fraction of Cdk2, the main CDK partner for cyclin E, coeluted with cyclin E in all cell lines ( Figure 6 and data not shown). Some dierences in the elution pro®les of p21 and p27 were observed between cell lines, suggesting that these CKIs are dierently distributed between a range of complexes. In MDA-MB-157 cells p21 coeluted with cyclin E but the majority of p21 eluted at lower apparent molecular mass in the MCF-7, 184 and T-47D cell lines, coeluting with cyclin D1 (Figure 7c) . A broader distribution was observed for p27 (Figure 7d ), which coeluted with both cyclin D1 and cyclin E in the majority of the cell lines. The MDA-MB-157 cell line, however, exhibited two distinct peaks of p27 protein rather than one broad peak, the lower molecular weight peak overlapping with the *200 kDa peak of cyclin E protein in fraction 5 (Figure 7) .
The Western blot data revealed that discrete pools of cyclin-CDK complexes existed, diering in their molecular weights and therefore, their composition. When cyclin E-Cdk2 activity was measured for selected fractions the analysis revealed clear dierences in speci®c activity of the cyclin E-associated kinases of diering apparent molecular weights (Figure 8a ). The very high molecular weight form (4400 kDa, fractions Fraction Number Figure 6 Western blots of cyclin D1 and E, Cdk2 and -4, p21 and p27 proteins from MCF-7 cell lysate fractions eluted from a Superdex 200 gel ®ltration column. Aliquots of each fraction from the gel ®ltration column were acetone precipitated and the retrieved protein boiled in SDS sample buer before being separated by SDS ± PAGE and transferred to nitrocellulose. The resultant ®lters were blotted with antibodies speci®c for cyclin D1, cyclin E, p21, p27, Cdk2 and Cdk4. The void volume was 46 ml and 3 ml fractions were collected from 55 ml. Elution of molecular weight standard proteins (ferritin, 440 kDa; catalase, 232 kDa; ovalbumin, 43 kDa) is indicated at the top 1 and 2) harboured signi®cant kinase activity, up to 50% or more of the total, despite accounting for a small minority of the cyclin E protein (typically 510%). The trailing edge of cyclin E protein (fraction 7) was also of high speci®c activity and in T-47D cells this fraction represented the major peak of kinase activity, consistent with the increased abundance of cyclin E in this fraction relative to the other cell lines. In all the cell lines examined the major peak of cyclin E protein was relatively inactive, typically accounting for 530% of the activity but 80 ± 90% of the protein. To investigate the basis for the dierences in speci®c activity across the elution pro®le, the composition of cyclin E immunoprecipitates from representative fractions was examined. The largely inactive complexes in fraction 5 contained abundant p21 and p27 (Figure 9b ). However the cyclin E complexes with high speci®c activity, from fractions 1 and 7, were relatively lacking in p21 and p27 ( Figure  9b ). In contrast to the results presented in Figure 8a for cyclin E-Cdk2 activity, Cdk4 activity displayed a similar elution pro®le to cyclin D1 and Cdk4 protein.
All three parameters showed a peak at *200 kDa in all cell lines (Figure 8b ). There was no Cdk4 activity associated with the lower molecular weight,`free' . The void volume was 46 ml and 3 ml fractions were collected from 55 ml. Elution of molecular weight standard proteins (ferritin, 440 kDa; catalase, 232 kDa; ovalbumin, 43 kDa) is indicated at the top cyclin D1 and Cdk4. Interestingly, immunoprecipitation studies revealed that the cyclin D1 complexes from fraction 5 contained the highest proportion of bound p21 and p27 (Figure 9a ) even though this was the fraction with the highest Cdk4 activity (Figure 8b ).
Discussion
The panel of breast cancer cell lines employed in this study provided a model for the diverse phenotypes found in clinical breast cancer. The eects of cyclin expression on cyclin-CDK-CKI complex formation and kinase activity were examined, revealing a number of relationships. Cyclin D1 binding to Cdk4 and Cdk2 was correlated with cyclin D1 abundance. In contrast, cyclin D1-Cdk6 complexes were much more abundant in normal breast epithelial cells than in breast cancer cell lines expressing similar levels of cyclin D1 and Cdk6. Cyclin E-Cdk2 complex formation was correlated with cyclin E expression. The level of p27 . The void volume was 46 ml and 3 ml fractions were collected from 55 ml. Elution of molecular weight standard proteins is indicated at the top. (a) Cyclin E-associated kinase activity from fractionated cell lysates. Cyclin E complexes were immunoprecipitated from the ®rst eight fractions of each gel ®ltration experiment. The immune complexes were used in in vitro kinase assays with histone H1 as substrate. Phosphorylated substrate was separated via SDS ± PAGE and the gel exposed to X-ray ®lm. The graph presents the densitometric value of the phosphorylated substrate from each fraction. (b) Cdk4 activity from fractionated cell lysates. Cyclin D1 complexes were immunoprecipitated from fractions 1, 3 ± 7, 9 and 11 of each gel ®ltration experiment. The immune complexes were then used in in vitro kinase assays with GST-pRB as substrate. Phosphorylated substrate was separated via SDS ± PAGE and the gel exposed to X-ray ®lm. The graph presents the densitometric value of the phosphorylated substrate from each fraction Figure 9 Composition of cyclin E and cyclin D1 complexes in breast epithelial cell lysate fractions eluted from a Superdex 200 gel ®ltration column. The void volume was 46 ml and 3 ml fractions were collected from 55 ml. (a) Composition of cyclin D1 complexes from fractionated MDA-MB-134 cell lysate. Cyclin D1 was immunoprecipitated from fractions 3, 5, 7 and 9 of the MDA-MB-134 cell lysate eluted from the gel ®ltration column. The immune complexes were separated by SDS ± PAGE and blotted for the presence of cyclin D1, p21 and p27 using antibodies speci®c to these proteins. (b) Composition of cyclin E complexes from fractionated MDA-MB-157 cell lysate. Cyclin E was immunoprecipitated from fractions 1, 3, 5 and 7 of the MDA-MB-157 cell lysate eluted from the gel ®ltration column. The immune complexes were separated by SDS ± PAGE and blotted for the presence of cyclin E, p21 and p27 using antibodies speci®c to these proteins correlated with cyclin D1 expression, consistent with data from clinical breast cancers (Fredersdorf et al., 1997) and the observation that constitutive expression of ectopic cyclin D1 induces p27 . Similarly, the correlation between cyclin D1 and p21 expression is consistent with the ®nding that ectopic cyclin D1 induction increased p21 expression through an E2F-dependent mechanism (Hiyama et al., 1997) . Overall, the most notable observation of the present study was that there was no strong relationship between cyclin D1 and cyclin E expression and the corresponding kinase activity.
Gel ®ltration analysis of breast cell lysates provided potential explanations for this lack of correlation. A substantial proportion of cyclin E protein was present in p21/p27-rich, inactive complexes such that only a small percentage of cyclin E protein was responsible for the kinase activity. For example, in the MDA-MB-157 cell line *90% of the overexpressed cyclin E was in catalytically inactive complexes. This observation supports data indicating that, even at the peak of estrogen-induced cyclin E-Cdk2 activity in MCF-7 breast cancer cells, the active cyclin E-Cdk2 complexes represented only a minor proportion of those present and were relatively devoid of CKIs (Planas-Silva and Weinberg, 1997; Prall et al., 1997) . Formation of these active complexes thus appears to be a more important determinant of cyclin E-Cdk2 activity than cyclin E abundance. The active cyclin E complexes had apparent molecular weights greater than anticipated if the complexes only contained cyclin, CDK and CKI, suggesting that they also contained other proteins. While these are as yet unidenti®ed, likely candidates with demonstrated cyclin E-Cdk2 binding ability include known and potential substrates such as the pRB-related proteins p107 and p130, E2F, adaptor proteins like the p300 transcriptional coactivator, or homologues of suc1-CKS family of CDK binding proteins (Parge et al., 1993; La Thangue, 1994; Sidle et al., 1996; Perkins et al., 1997) . Indeed, p107 and E2F are complexed to the overexpressed cyclin E protein in the MDA-MB-157 cell line (Gray-Bablin et al., 1996) . Furthermore, recent data from this laboratory indicate that the very high molecular weight, active cyclin ECdk2 complexes in oestrogen-stimulated MCF-7 cells contain p130 (Prall, Rogan, Musgrove, Watts and Sutherland, submitted) . Given the large range of molecular weights encompassed by the active fractions it is likely that several distinct complexes, perhaps with dierent speci®c activities, were present. Cyclin D1 levels varied over *3-fold range with the exception of the MDA-MB-134 cells, which displayed more than ®vefold overexpression of cyclin D1. There were no cell lines available with between 3 ± 5-fold overexpression of cyclin D1 (see Figure 2c) , although studies on primary breast cancers suggest that this range of expression exists in clinical breast cancer (Buckley et al., 1993; Hui et al., 1996) . This limited range of cyclin D1 expression levels covered by the majority of cell lines may have precluded the identi®cation of a positive correlation between cyclin D1 expression and Cdk4 activity. Nevertheless, the MDA-MB-134 cell line displayed the highest levels of both cyclin D1 expression and Cdk4 activity and so it is possible that high degrees of cyclin D1 overexpression are accompanied by increased Cdk4 activity.
Although there was an increase in Cdk4 activity in the MDA-MB-134 cell line it was only *2-fold even though there was *5-fold overexpression of cyclin D1. The presence of p21 and p27 in the cyclin D1-Cdk4 complexes is an unlikely explanation for this observation since following separation of cell lysate using gel ®ltration in all cell lines the fractions with the greatest Cdk4 activity contained the most p21 and p27. Furthermore, catalytically active p27 complexes have been described in a number of cell types including T-47D breast cancer cells (Florenes et al., 1996; Soos et al., 1996; Reynisdottir and Massague, 1997; unpublished data) . However, MDA-MB-134 cells displayed unbound cyclin D1 and an abundance of cyclin D1-Cdk2 complexes, which are not phosphorylated by the CDK-activating kinase (CAK) and are thus catalytically inactive (Higashi et al., 1996) . Similarly, unbound cyclin D1 or cyclin D1-Cdk2 and cyclin D1-Cdk6 complexes were detected in a number of the other cell lines. Taken together these data indicate that a varying proportion of cyclin D1 was not available for Cdk4 binding because it was complexed with other CDKs or was apparently free; this may in part explain the lack of correlation between cyclin D1 protein level and Cdk4 activity in the breast cell lines examined. Furthermore, preliminary data suggested that Cdk4 activity in MDA-MB-134 cells was reduced by only *30% following immunodepletion of cyclin D1. Therefore,¯uctuations in cyclin D1 expression may not aect Cdk4 activity as dramatically as would be expected if cyclin D1-Cdk4 complexes were the sole contributor to the measurable Cdk4 activity.
The observation that the active cyclin D1-Cdk4 fractions were rich in p21 and p27 provides support for the recent proposition that p21 and p27 have additional roles as adaptor molecules . In vitro experiments showed that the addition of p21 or p27 was sucient to form complexes from puri®ed cyclin D1 and Cdk4 or Cdk6 and that the quantity of the assembled complex was directly dependent on the level of inhibitor present . Similarly, in breast epithelial cells there was a relationship between the level of Cdk4 and the amount of p27 complexed to cyclin D1. Additionally, there was a relationship between p21 and Cdk2 association with cyclin D1, suggesting that p21 may be an adaptor for kinases other than Cdk4 and Cdk6 in these cells. The lack of correlation between the levels of Cdk4 and p21 bound to cyclin D1 may indicate preferential binding of cyclin D1 and p21 to Cdk2. Hence, the rise in p21 and p27 levels with increasing cyclin D1 expression may serve to stabilize cyclin D1-Cdk4 and cyclin D1-Cdk2 complexes. In contrast with cyclin D1-Cdk4 and cyclin D1-Cdk2, cyclin D1-Cdk6 complexes were not readily detectable in the majority of the breast cancer cell lines, despite the presence in some cell lines of levels of Cdk6 similar to those in the 184 cells where cyclin D1-Cdk6 complexes were clearly present. The reasons for this observation are unknown. Possibly Cdk6 competes poorly for p21, p27 or some other unidenti®ed binding factor or Cdk6 may be prevented from binding to cyclin D1 by a Cdk6-speci®c CKI such as p18 INK4C (Guan et al., 1994; Hirai et al., 1995) .
There was also a relationship between the amount of p27 and Cdk2 complexed to cyclin E. However, p27 appeared to have an inhibitory role when bound to cyclin E-Cdk2 complexes, consistent with the lack of histone H1 kinase activity in p27 immune complexes (Soos et al., 1996; unpublished data) . In vitro experiments have shown that puri®ed cyclin E and Cdk2 can bind without any accessory factors or CAK phosphorylation of the CDK subunit, requirements which are essential for the ecient binding of D-type cyclins (Matsushime et al., 1994; Desai et al., 1995; LaBaer et al., 1997) . Therefore, p27 is unlikely to be acting as an adaptor but rather as a kinase inhibitor in the cyclin E complexes from these breast cells.
Although the majority of cyclin E protein and a varying proportion of cyclin D1 protein does not associate with CDK activity these G 1 cyclins may serve other CDK-indpendent functions in breast epithelial cells. CDK-independent activation of the estrogen receptor by cyclin D1 has already been described (Neuman et al., 1997; Zwijsen et al., 1997) and both cyclin D1 and p27 expression levels have been correlated with ER positivity (Hui et al., 1996; Catzavelos et al., 1997) . Furthermore, cyclins D1 and E may have targets other than pRB that remain to be identi®ed. In support of this, those patients whose breast cancers exhibit low cyclin D1, mutant pRB and high cyclin E expression tend to have a worse prognosis than patients with high cyclin D1, wild-type pRB and low cyclin E (Nielsen et al., 1997) arguing that cyclin E has some pRB-independent pathogenic role in the breast cancer. A possibility suggested by the lack of relationship between cyclin D1 overexpression and increased Cdk4 activity is that some of the substrates phosphorylated by cyclin D1-Cdk4 but not cyclin D3-Cdk4 are important for the oncogenic actions of cyclin D1. Finally, there is emerging evidence that these cell cycle proteins are involved in the regulation of dierentiation (reviewed in Kranenburg et al., 1995) , apoptosis Sofer-Levi and Resnitzky, 1996) and cellular adhesion (Zhu et al., 1996) in addition to proliferative control.
The potential multiplicity of cyclin-CDK function may explain why the activity of these complexes had little bearing on the fraction of cells in S phase or the doubling times of the cells. Other studies have shown that increased cell proliferation is often correlated with increased levels of cyclin D1 and cyclin E in primary tumours (Dutta et al., 1995; Porter et al., 1997) . However, since some breast tumours do not have concordant cyclin E expression and proliferative status (Dutta et al., 1995; Porter et al., 1997) , the correlation of cyclin E expression with poorer prognosis is not always explicable in terms of cell proliferation (Porter et al., 1997) .
In conclusion, there was no signi®cant relationship between cyclin D1 and cyclin E and Cdk4 or Cdk2 activity in the breast epithelial cell lines examined, although the cyclin D1-overexpressing MDA-MB-134 cells had relatively more Cdk4 activity than the remaining cell lines. Gel ®ltration chromatography revealed a likely reason for this lack of association was that most of the cyclin E protein and a varying fraction of the cyclin D1 protein (depending on the cell line) was in CDK-inactive fractions. Thus, the possibility exists that these proteins may be exerting some of their oncogenic potential through CDK independent mechanisms and/or may be involved in functions other than the control of proliferation. These results would not necessarily have been predicted from published studies where the consequences of acute overexpression of these cyclins have been investigated. Rather, these observations re¯ect more closely the ®ndings in clinical breast cancer where overexpression of G 1 cyclins is not always associated with increased proliferative status. 
Materials and methods
Cell
S-phase determination
Analytical DNA¯ow cytometry was used to determine cell cycle phase distribution as described previously (Musgrove et al., 1989) . Brie¯y, the cells were treated with 0.2% Triton X-100 to permeabilize the cell membranes and stained with a combination of DNA-speci®c dyes overnight before analysis.
Western blot analysis, immunoprecipitation and kinase assays
For immunoprecipitation or Western blot analysis cell monolayers in exponential growth were washed twice in ice-cold PBS and then scraped into the following lysis buer: 50 mM HEPES (pH 7.5), 150 mM NaCl, 10% (v/v) glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM PMSF, 200 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 100 mM NaF. The lysates were incubated on ice for 5 min before clearing cell debris by centrifugation (14 000 g, 5 min) and stored at 7708C until use.
For Western analyses equal amounts of protein were separated by SDS ± PAGE and transferred to nitrocellulose ®lters. The membrane was stained with 0.5% Ponceau S in 10% acetic acid to monitor protein loading and discarded if equivalent loading was not demonstrated. Non-speci®c binding was blocked in 5 ± 10% skim milk powder in TBS/ Triton (10 mM Tris (pH 7.4), 150 mM NaCl, 0.1% Triton X-100), followed by incubation for 2 h at room temperature in primary antibody, typically at a concentration of 1 mg/ml in TBS/BSA (10 mM Tris (pH 7.4), 150 mM NaCl, 5% BSA).
Where the proteins of interest were of suciently dierent mobility, several primary antibodies were used either sequentially or simultaneously. Primary antibodies used for blotting were: cyclin E (HE12), Cdc2p34 (17), Cdk2 (M2), Cdk4 (C-22), Cdk5 (C-8), Cdk6 (C-21), from Santa Cruz Biotechnology, Santa Cruz, CA, USA; cyclin D1 (DCS6) from Novacastra Laboratories, Newcastle-Upon-Tyne, UK; p21 (cat no. C224420) and p27 (cat no. K25020) from Transduction Labs, Lexington, KY; sheep anti-mouse and donkey antirabbit horseradish peroxidase linked secondary antibodies were from Amersham Australia, Castle Hill, NSW, Australia. Filters were then incubated with the appropriate secondary antibody (1 : 2000 in 5% skim milk powder) for 1 h before enhanced chemiluminescence (ECL) detection (Amersham or Dupont NEN, Boston, MA). Densitometric analysis of autoradiographs was performed using a Molecular Dynamics (Sunnyvale, CA) Personal Densitometer SL and IP LabGel analysis software (Signal Analytics, VA). Quantitation of protein levels by this method was linear over the range of intensities measured see also Sweeney et al., 1997) . Relationships between expression levels were determined by simple regression analysis using the software program StatView SE+Graphics (Abacus Concept Inc.).
For use in kinase assays, cell monolayers were washed once in PBS and scraped into the following lysis buer on ice: 50 mM HEPES (pH 7.5), 1 mM DTT, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 0.1% Tween-20, 10% glycerol, 10 mM b-glycerophosphate, 1 mM NaF, 0.1 mM orthovanadate, 10 mg/ml leupeptin, 10 mg/ml aprotinin and 0.1 mM PMSF. Cells were vortexed for 15 s every 10 min for 1 h before centrifugation to remove cell debris. Proteins were immunoprecipitated using antibodies raised against either Cdk4 (H-22 from Santa Cruz) or cyclin E (C-19 from Santa Cruz). The eciency of Cdk4 or cyclin E immunoprecipitation was typically around 80 ± 90%, even for the overexpressed cell lines, con®rming that the amount of antibody used in these experiments was at saturating concentrations. Lysates (500 mg for Cdk4; 100 mg for cyclin E) were precleared for 1 h at 48C with Protein A beads that had been equilibrated in lysis buer. Lysates were incubated for 1 ± 3 h at 48C with the antibody then 40 ml protein Asepharose beads (50 : 50 slurry with lysis buer for cyclin E kinase assay and 25 : 75 slurry for Cdk4 kinase assay) was added and incubated for 0.5 ± 1 h. The beads were then washed twice in ice cold lysis buer and twice in 50 mM HEPES (pH 7.5), 1 mM DTT.
Samples used to analyse immunoprecipitated proteins were boiled for 3 min in SDS sample buer (60 mM Tris-HCl (pH 6.8), 10% (v/v) glycerol, 2% SDS, 5% b-mercaptoethanol) before SDS ± PAGE; visualization of the immunoprecipitated proteins was as described above for Western analysis. Samples to be used in kinase assays had 20 ml of substrate in HEPES/DTT (10 mg bacterially expressed GST-pRB fusion protein prepared as described previously (Prall et al., 1997) or 10 mg histone H1 (Sigma Chemicals) added along with 10 ml of 36 kinase buer giving a ®nal concentration of: 50 mM HEPES (pH 7.5), 1 mM DTT, 2.5 mM EGTA, 10 mM MgCl 2 , 20 mM ATP, 10 mCi [g-32 P]ATP, 0.1 mM sodium orthovanadate, 1 mM NaF, 10 mM b-glycerophosphate. The amount of substrate was con®rmed to not be limiting even for the samples that overexpressed cyclin E or cyclin D1. Samples were mixed gently to resuspend beads and incubated at 308C for 30 min with gentle mixing every 10 min. The reaction was terminated by the addition of 36SDS sample buer (®nal concentration: 60 mM Tris-HCl (pH 6.8), 10% (v/v) glycerol, 2% SDS, 5% b-mercaptoethanol). The samples were then incubated at 908C for 3 min before separation by SDS ± PAGE. Relative intensities were quantitated by densitometry after exposure of the dried gel to X-ray ®lm.
Gel ®ltration chromatography
Cell lysates were prepared as described above for kinase assays then ®ltered through a 0.22 mM MILLEX-GV4 ®lter (Millipore, Lane Cove, NSW, Australia). The ®ltered lysate samples were then fractionated on a Hi-Load Superdex 200 prep-grade column using a fast protein liquid chromatography system (both from Pharmacia Biotech, Uppsala, Sweden). The void volume of the column was 46 ml, after 55 ml had eluted 3 ml fractions were collected for another 39 ml. Calibration of the column using a high molecular weight gel ®ltration calibration kit (Pharmacia) indicated that these fractions contained proteins of apparent molecular mass 20 ± 600 kDa. The column was developed with a¯ow rate of 1.2 ml/min with 20 mM HEPES, pH 7.5, 250 mM NaCl, 1 mM EDTA, 0.1% (v/v) b-mercaptoethanol. Acetone precipitation was used to concentrate the protein prior to Western analysis by aliquoting 540 ml of each fraction into 2.4 ml of acetone and 20 mg of carrier BSA; the fraction was then placed at 7708C overnight. Precipitated protein was pelleted at 15 000 g, 15 min, 48C and resuspended in SDS sample buer.
